Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The purpose of this extension study was to assess the long-term efficacy and safety of gemigliptin 50 mg in patients with type 2 diabetes mellitus (T2DM). Patients with T2DM who had completed the initial 24-week study comparing gemigliptin monotherapy with placebo were eligible to enrol. In the open-label, 28-week extension study, all enrolled patients received gemigliptin, regardless of the treatment received during the initial 24-week study period. The mean reduction±standard deviation (SD) in glycosylated hemoglobin (HbA1c) observed after 24 weeks of treatment (-0.6%±1.1%) was further decreased for the gemi-gemi group and the mean change in HbA1c at week 52 from baseline was -0.9%±1.2% (P<0.0001). For the pbo-gemi group, HbA1c decreased after they were switched to gemigliptin, and the mean change in HbA1c at week 52 from baseline was -0.7%±1.2% (P<0.0001). Furthermore, the overall incidence of adverse events demonstrated that gemigliptin was safe and well tolerated up to 52 weeks.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369212 | PMC |
| http://dx.doi.org/10.4093/dmj.2020.0047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concepts for the Integration and Implementation of mHealth Apps for Patients With Mental Disorders: Scoping Review.
J Med Internet Res
September 2025
Institute for Health Care Management and Research, University of Duisburg-Essen, Essen, Germany.
Background: Mental and behavioral disorders affect approximately 28% of the adult population in Germany per year, with treatment being provided through a diverse health care system. Yet there are access and capacity problems in outpatient mental health care. One innovation that could help reduce these barriers and improve the current state of care is the use of mobile health (mHealth) apps, known in Germany as Digitale Gesundheitsanwendungen (DiGA).
View Article and Find Full Text PDFA causal framework for the drivers of animal social network structure.
PLoS Comput Biol
September 2025
Department of Human Behaviour, Ecology and Culture, Max Planck Institute for Evolutionary Anthropology, Leipzig, Germany.
A major goal of behavioural ecology is to explain how phenotypic and ecological factors shape the networks of social relationships that animals form with one another. This inferential task is notoriously challenging. The social networks of interest are generally not observed, but must be approximated from behavioural samples.
View Article and Find Full Text PDFOutcomes and complications among nonagenarians undergoing cardiac surgery: A scoping review.
PLoS One
September 2025
Department of Cardiac Surgery, Epworth Eastern Hospital, Box Hill, Victoria, Australia.
Introduction: This review was aimed at understanding the scope of evidence regarding outcomes and complications in nonagenarians (90-99 years of age) undergoing open cardiac surgery.
Methods: The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Review Protocol guidelines. A search of three databases, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, identified articles pertaining to nonagenarians undergoing various open cardiac surgical procedures.
A Scoping Review of Women with Physical Disabilities and Cervical Cancer Screening.
J Womens Health (Larchmt)
September 2025
Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, Michigan, USA.
Women with physical disabilities (WWPDs) have lower screening rates for cervical cancer than the general population globally. This scoping review aims to define the type of studies and content of studies currently available to promote cervical cancer screening among WWPDs. It seeks to clarify the type of disabilities WWPDs have that lead to the poorest participation in cervical cancer screening and highlight how health care systems can address the disclosed gaps.
View Article and Find Full Text PDFHistopathologic and Clinical Characteristics of Cutaneous Toxicities of Tyrosine Kinase Inhibitors: Insights Into Pathologic Mechanisms From a Retrospective Cohort.
Am J Dermatopathol
September 2025
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Background: Dermatologic adverse events (dAEs) are prevalent with BCR-ABL tyrosine kinase inhibitors (TKIs), affecting quality of life and treatment adherence. Despite their prevalence, underlying mechanisms of toxicity remain unclear. We sought to characterize dAEs across TKI generations to elucidate mechanisms driving toxicities.
View Article and Find Full Text PDF